Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Neuphoria Therapeutics Inc. (NEUP) had Return on Tangible Equity of -6.65% for the most recently reported fiscal year, ending 2025-06-30.
| Income Statement Financials | |
$15.65M |
|
$-0.37M |
|
-- |
|
$15.65M |
|
$16.78M |
|
$-1.13M |
|
$0.29M |
|
$-0.84M |
|
$-0.84M |
|
$-0.37M |
|
$-0.37M |
|
$-0.37M |
|
$-0.37M |
|
$-1.13M |
|
$-0.47M |
|
1.62M |
|
1.62M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$15.04M |
|
$0.00M |
|
$13.55M |
|
$28.59M |
|
$4.22M |
|
-- |
|
$5.37M |
|
$9.59M |
|
$19.00M |
|
$5.56M |
|
$19.00M |
|
1.98M |
|
| Cash Flow Statement Financials | |
$0.08M |
|
-- |
|
$1.53M |
|
$12.69M |
|
$14.29M |
|
$1.60M |
|
$0.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-7.21% |
|
-7.21% |
|
-2.98% |
|
-5.35% |
|
-2.36% |
|
$0.08M |
|
-- |
|
-- |
|
-- |
|
0.55 |
|
-- |
|
1309.80 |
|
0.28 |
|
-1.95% |
|
|
Return on Tangible Equity |
-6.65% |
-1.29% |
|
-1.95% |
|
$9.61 |
|
$0.05 |
|
$0.05 |
|